TICKERNERD
Menu
ROIVROIVHealthcare · Biotechnology

ROIV Stock Forecast: Roivant Sciences Ltd. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$36
−0.22% on the day

The 12 Wall Street analysts covering Roivant Sciences Ltd. hold a median 12-month price target of $41 — +13.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 15 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$26.1B
Ticker Nerd rank
36 / 100
Median analyst target
$41
Analysts covering
12
Total return, dividends reinvested
1W
−0.4%
1M
+3.7%
YTD
+66.8%
1Y
+208.1%
From 52W high
−1.7%
From 52W low
+211.0%
$12
$37
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ROIV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Roivant Sciences Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
36 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
98
Volatility
90
Issuance
54
Growth
54
Value
48
Revisions
40
Quality
34
Accruals
15
Size
9

Momentum (98): The shares have been drifting up relative to others.

Accruals (15): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (9): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ROIV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ROIV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50Oct 25Jan 26Apr 26Jul 26ROIVHigh $50Median $41Low $37

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says12 analysts
11 Buy1 Hold0 Sell
Low $37Median $41High $50

The green dot is the last close — the median target sits +13.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
10 Aug 2026CitigroupMaintainsBuy$42 → $46
7 Aug 2026GuggenheimMaintainsBuy$36 → $42
7 Aug 2026HC Wainwright & Co.MaintainsBuy$34 → $41
26 May 2026GuggenheimMaintainsBuy$30 → $36
26 May 2026GuggenheimMaintainsBuy—
21 May 2026CitigroupMaintainsBuy$35 → $42
21 May 2026CitigroupMaintainsBuy—
21 May 2026HC Wainwright & Co.ReiteratesBuy—
21 May 2026HC Wainwright & Co.ReiteratesBuy$34
21 May 2026TD CowenMaintainsBuy—
21 May 2026TD CowenMaintainsBuy$38 → $41
16 Apr 2026Piper SandlerMaintainsOverweight—
4 Mar 2026HC Wainwright & Co.MaintainsBuy—
10 Feb 2026CitigroupMaintainsBuy—
10 Feb 2026HC Wainwright & Co.MaintainsBuy—
9 Feb 2026GuggenheimMaintainsBuy—
15 Dec 2025Goldman SachsMaintainsBuy—
15 Dec 2025Leerink PartnersMaintainsOutperform—
12 Dec 2025HC Wainwright & Co.MaintainsBuy—
11 Nov 2025CitigroupMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ROIV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ROIV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
3
Fundamentals

Roivant Sciences Ltd. (ROIV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
1.9×

Cheaper than 70% of US stocks

Price / sales
3471.6×

Cheaper than 1% of US stocks

Price / book
5.8×

Cheaper than 19% of US stocks

EV / EBITDA
−17.0×

Cheaper than 88% of US stocks

Growth & margins
Revenue growth (YoY)
−33.5%

Higher than 8% of US stocks

Earnings growth (YoY)
−33.5%

Higher than 14% of US stocks

Gross margin
80.3%

Higher than 91% of US stocks

Operating margin
−25408.1%

Higher than 1% of US stocks

Net margin
84.4%

Higher than 99% of US stocks

Returns & dividend
Return on equity
−8.5%

Higher than 37% of US stocks

Return on assets
−16.5%

Higher than 22% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ROIV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ROIVRoivant Sciences Ltd.$26.1B
36
MRNAModerna, Inc.$25.3B
75
INSMInsmed, Inc.$27.0B
84
INCYIncyte Corp.$24.0B
90
ALNYAlnylam Pharmaceuticals, Inc.$30.2B
54
RPRXRoyalty Pharma plc$33.7B
86
RVMDRevolution Medicines, Inc.$42.5B
35

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Roivant Sciences Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ROIV news & analysis

Roivant Sciences: The Balance Sheet Has Become A Strategic Weapon

Seeking Alpha · 8 Aug 2026positive

Roivant Sciences is transitioning from an asset-monetization platform toward a commercial-stage biopharma, supported by a large cash position that reduces near-term dilution risk. Its drug brepocitinib has received FDA Priority Review for dermatomyositis and could gain approval by September 2026, with label expansions targeting an opportunity of more than 280,000 patients.

Why it matters — A ROIV watcher would care because the company's strengthened balance sheet and upcoming brepocitinib regulatory decision mark a shift away from relying on equity markets toward self-funded commercialization and pipeline development.

Roivant Sciences Q1 Earnings Call Highlights

MarketBeat · 7 Aug 2026positive

Roivant Sciences held its Q1 earnings call, during which it outlined expectations for a busy second half of 2026. The company anticipates a potential launch of brepocitinib in dermatomyositis, several clinical readouts, and additional regulatory discussions across its pipeline.

Why it matters — A ROIV watcher would care because the company's pipeline progress, including a potential brepocitinib launch and upcoming clinical readouts, signals significant near-term catalysts.

Roivant Sciences Ltd. (ROIV) Q1 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Roivant Sciences Ltd. (ROIV) held its Q1 2026 earnings call, the transcript of which was published by Seeking Alpha. The call covered the company's first-quarter 2026 financial results and management commentary.

Why it matters — A ROIV watcher would care because the earnings call transcript provides management's own discussion of the company's Q1 2026 performance and outlook directly from the source.

Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates

Zacks Investment Research · 6 Aug 2026negative

Roivant Sciences reported a first-quarter loss of $0.33 per share, matching the Zacks Consensus Estimate. The company's results missed revenue estimates for the quarter.

Why it matters — A revenue miss alongside the in-line loss signals weaker-than-expected top-line performance for a company whose quarterly results investors track closely.

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

GlobeNewsWire · 6 Aug 2026positive

Immunovant provided corporate updates and reported financial results for the quarter ended June 30, 2026, stating that all IMVT-1402 clinical development timelines remain on track across studies in Graves' disease, myasthenia gravis, CIDP, difficult-to-treat rheumatoid arthritis, Sjögren's disease, and cutaneous lupus erythematosus. The company noted its current cash balance provides runway to the potential launch of IMVT-1402 in Graves' disease, and Roivant will host a conference call and webcast on August 6, 2026.

Why it matters — For Roivant watchers, this update confirms the key IMVT-1402 program is proceeding on schedule and is funded through a potential Graves' disease launch.

FAQ

Frequently asked questions about ROIV stock

What is the ROIV stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Roivant Sciences Ltd. have a median 12-month price target of $41, with estimates ranging from $37 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ROIV stock a buy right now?

Of the 12 analysts covering Roivant Sciences Ltd., 11 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Roivant Sciences Ltd. 36 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ROIV?

As at 15 Aug 2026, Roivant Sciences Ltd. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).

Will ROIV stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +13.3% from the last close, and Ticker Nerd's factor model ranks Roivant Sciences Ltd. 36 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ROIV stock forecast for 2030?

No analyst covering Roivant Sciences Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ROIV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $37 to $50 over the next 12 months.

How has ROIV stock performed over the past year?

Roivant Sciences Ltd. returned +208.1% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Roivant Sciences Ltd. do?

Roivant Sciences Ltd. is an American multinational healthcare company that develops transformative medicines and technologies by creating agile, focused subsidiaries called Vants.

What is the latest news on ROIV?

The most recent item we track (Seeking Alpha, 8 Aug 2026): "Roivant Sciences: The Balance Sheet Has Become A Strategic Weapon". Roivant Sciences is transitioning from an asset-monetization platform toward a commercial-stage biopharma, supported by a large cash position that reduces near-term dilution risk. Its drug brepocitinib has received FDA Priority Review for dermatomyositis and could gain approval by September 2026, with label expansions targeting an opportunity of more than 280,000 patients.

Company

About Roivant Sciences Ltd.

Roivant Sciences Ltd. is an American multinational healthcare company that develops transformative medicines and technologies by creating agile, focused subsidiaries called Vants. These Vants target specific therapeutic areas, including autoimmune diseases through Immunovant, severe autoimmune conditions via Priovant, and pulmonary diseases with Pulmovant. The company applies technology across drug discovery, development, and commercialization to accelerate the delivery of innovative therapies to patients. Roivant Sciences Ltd. maintains a broad pipeline of investigational drugs across multiple areas such as immunology, dermatology, rare diseases, and inflammatory conditions. Notable Vants include Kinevant for rare autoimmune and inflammatory diseases, and health technology units like Datavant for healthcare data sharing and Lokavant for clinical trial optimization. Founded in 2014 and headquartered in New York City with offices in Boston and Basel, Roivant Sciences Ltd. operates as a parent to these specialized entities, aligning incentives for efficient execution in the biopharmaceutical sector.

CEO Mr. Matthew Gline · 721 employees · United Kingdom · https://roivant.com